Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Previous radiotherapy improves treatment responses and causes a trend toward longer time to progression among patients with immune checkpoint inhibitor-related adverse events.
Jokimäki A, Hietala H, Lemma J, Karhapää H, Rintala A, Kaikkonen JP, Sunela K, Boman E, Jukkola A, Tiainen S, Seppälä J, Rönkä A, Hakkarainen H, Kärnä A, Iivanainen S, Koivunen J, Auvinen P, Hernberg M, Kuusisto M, Selander T, Kuittinen O. Jokimäki A, et al. Among authors: hakkarainen h. Cancer Immunol Immunother. 2023 Oct;72(10):3337-3347. doi: 10.1007/s00262-023-03494-4. Epub 2023 Jul 24. Cancer Immunol Immunother. 2023. PMID: 37486396 Free PMC article.
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino Á, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, Utriainen T, Fu C, Uemura M, Méndez-Vidal MJ, Maughan BL, Joensuu H, Thiele S, Li R, Kuss I, Tombal B; ARASENS Trial Investigators. Smith MR, et al. N Engl J Med. 2022 Mar 24;386(12):1132-1142. doi: 10.1056/NEJMoa2119115. Epub 2022 Feb 17. N Engl J Med. 2022. PMID: 35179323 Free PMC article. Clinical Trial.
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Haas NB, Gurney H, Sawrycki P, Mahave M, Gross-Goupil M, Zhang T, Burke JM, Doshi G, Melichar B, Kopyltsov E, Alva A, Oudard S, Topart D, Hammers H, Kitamura H, McDermott DF, Silva A, Winquist E, Cornell J, Elfiky A, Burgents JE, Perini RF, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2024 Apr 18;390(15):1359-1371. doi: 10.1056/NEJMoa2312695. N Engl J Med. 2024. PMID: 38631003 Clinical Trial.
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Gurney H, Chang YH, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Burgents JE, Xu L, Imai K, Quinn DI, Choueiri TK; KEYNOTE-564 Investigators. Powles T, et al. Lancet Oncol. 2022 Sep;23(9):1133-1144. doi: 10.1016/S1470-2045(22)00487-9. Lancet Oncol. 2022. PMID: 36055304 Free article. Clinical Trial.
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2021 Aug 19;385(8):683-694. doi: 10.1056/NEJMoa2106391. N Engl J Med. 2021. PMID: 34407342 Free article. Clinical Trial.
Towards zero pollution vehicles by advanced fuels and exhaust aftertreatment technologies.
Saarikoski S, Järvinen A, Markkula L, Aurela M, Kuittinen N, Hoivala J, Barreira LMF, Aakko-Saksa P, Lepistö T, Marjanen P, Timonen H, Hakkarainen H, Jalava P, Rönkkö T. Saarikoski S, et al. Among authors: hakkarainen h. Environ Pollut. 2024 Apr 15;347:123665. doi: 10.1016/j.envpol.2024.123665. Epub 2024 Mar 1. Environ Pollut. 2024. PMID: 38432344 Free article.
Emissions from modern engines induce distinct effects in human olfactory mucosa cells, depending on fuel and aftertreatment.
Mussalo L, Avesani S, Shahbaz MA, Závodná T, Saveleva L, Järvinen A, Lampinen R, Belaya I, Krejčík Z, Ivanova M, Hakkarainen H, Kalapudas J, Penttilä E, Löppönen H, Koivisto AM, Malm T, Topinka J, Giugno R, Aakko-Saksa P, Chew S, Rönkkö T, Jalava P, Kanninen KM. Mussalo L, et al. Among authors: hakkarainen h. Sci Total Environ. 2023 Dec 20;905:167038. doi: 10.1016/j.scitotenv.2023.167038. Epub 2023 Sep 13. Sci Total Environ. 2023. PMID: 37709087 Free article.
Toxicity of exhaust emissions from high aromatic and non-aromatic diesel fuels using in vitro ALI exposure system.
Hakkarainen H, Järvinen A, Lepistö T, Salo L, Kuittinen N, Laakkonen E, Yang M, Martikainen MV, Saarikoski S, Aurela M, Barreira L, Teinilä K, Ihalainen M, Aakko-Saksa P, Timonen H, Rönkkö T, Jalava P. Hakkarainen H, et al. Sci Total Environ. 2023 Sep 10;890:164215. doi: 10.1016/j.scitotenv.2023.164215. Epub 2023 May 23. Sci Total Environ. 2023. PMID: 37230343 Free article.
85 results